![]() ![]() He received his undergraduate degree from VCU and is a graduate of the VCU/MCV School of Dentistry. John Kittrell has been taking care of Richmonders and their dental needs for over three decades. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS. ![]() Differential tolerance to morphine antinociception in assays of pain-stimulated vs. Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Negus SS, Neddenriep B, Altarifi AA, Carroll FI, Leitl MD, Miller LL. Pharmacological modulation of neuropathic pain-related depression of behavior: Effects of morphine, ketoprofen, bupropion and ∆9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Negus SS, Bilsky EJ, Pereira Do Carmo G, Stevenson GW. American Chemical Society, Washington, DC. Research and Development of Opioid-Related Ligands. Mu, delta and kappa opioid agonist effects in novel assays of pain-depressed behavior. ![]() Expression and treatment of pain-related behavioral depression. Abuse-related and abuse-limiting effects of methcathinone and the “bath salts” cathinone derivatives methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. PMCID: PMC4939093īonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS. Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys. Johnson AR, Banks ML, Blough BE, Lile JA, Nicholson KL, Negus SS. In Special Issue on Sex Differences in Psychopharmacology Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Lazenka MF, Suyama JS, Bauer CT, Banks ML, Negus SS. Repeated 7-day treatment effects with the 5-HT2C agonist lorcaserin and the 5-HT2A antagonist pimavanserin alone or in combination on cocaine vs. Intracranial self-stimulation (ICSS) to evaluate abuse potential of drugs. Invited “Circumspectives” Article: Neuropsychopharmacology, 2015 40:1815-1825. Agonist medications for the treatment of cocaine use disorder. Insights from preclinical choice models on treating drug addiction. Finally, our work has led us to develop and refine experimental strategies for the study of drug interactions.īanks ML, Negus SS. Second, we are developing novel and more sophisticated procedures to measure behaviors related to pain and addiction. First, we are working with medicinal chemistry colleagues to develop new medications that might be used to treat abuse of opioids and of CNS stimulants like cocaine. This central theme of our work has also stimulated research in three other directions. Our studies are giving us new insights into the mechanisms and potential interactions of pain and addiction, and we are also pioneering new strategies for development of safer analgesics with reduced abuse liability. Our laboratory is engaged in research to study factors that influence these pain-killing and abuse-related effects of opioids. Morphine-like opioid drugs are widely used to treat strong pain, but their use is limited by side effects that include high-abuse liability. Strategies for assessment of drug interactions.Development of novel procedures to assess analgesia and drug reinforcement.Development of medications to treat opioid and CNS stimulant addiction.Pharmacology of the analgesic and abuse-related effects of opioid analgesics.Department: Department of Pharmacology and ToxicologyĮmail: Robert Blackwell Smith Building, Room 760B ![]()
0 Comments
Leave a Reply. |